

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	FAAH-like anandamide transporter (FLAT)	<p>Cell culture and rodent studies suggest antagonizing FLAT could be useful for treating pain. In cell culture, expression of transgenic FLAT increased anandamide transport into cells compared with that seen using vehicle control. In mice, a FLAT antagonist decreased sensitivity to pain compared with vehicle. Next steps include optimizing FLAT antagonists as potential analgesics.</p> <p>IPI-940, an oral fatty acid amide hydrolase (FAAH) inhibitor from Infinity Pharmaceuticals Inc., Mundipharma International Ltd. and Purdue Pharma L.P., is in Phase I testing to treat pain.</p> <p>SAR411298, an FAAH inhibitor from Sanofi, is in Phase I testing to treat pain.</p> <p>V158866, a small molecule FAAH inhibitor from Vernalis plc, is in Phase I testing to treat pain.</p> <p>SciBX 4(47); doi:10.1038/scibx.2011.1334 Published online Dec. 8, 2011</p>	Patent pending; available for licensing	<p>Fu, J. <i>et al. Nat. Neurosci.</i>; published online Nov. 20, 2011; doi:10.1038/nn.2986</p> <p>Contact: Daniele Piomelli, University of California, Irvine, Calif. e-mail: piomelli@uci.edu</p>